Security key
02043Q107
ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY)
CUSIP: 02043Q107
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 2,726,794
- Total 13F value
- $818,030,342
- Share change
- +118,699
- SEC-reported price per share
- $301.03
- Number of holders
- 245
- Value change
- +$32,166,537
- Number of buys
- 126
- Number of sells
- 111
- Shares outstanding
- 133,131,695
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
245
Top holders
10
ALNY full security history
Ownership snapshot
Full 13F holder table
ALNYLAM PHARMACEUTICALS, INC. SEC filings
ALNYLAM PHARMACEUTICALS, INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of ALNY - ALNYLAM PHARMACEUTICALS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
01 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 11%
13D/G row: FMR LLC
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 11%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
11%
Capital World Investors
8.2%
Capital Research Global Investors
7.1%
VANGUARD CAPITAL MANAGEMENT LLC
5.4%
David E. I. Pyott
0.02%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
Company
|
11%
|
$4,875,294,782
14,640,525 shares
|
-$730,458,810 | 31 Mar 2026 |
| Capital World Investors |
13D/G
13F
Company
|
8.2%
|
$3,635,294,067
10,916,799 shares
|
$0 | 31 Mar 2026 |
| Capital Research Global Investors |
13D/G
13F
Company
|
7.1%
|
$3,153,903,273
9,471,181 shares
|
+$833,388,444 | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5.4%
|
$2,350,677,826
7,104,536 shares
|
$0 | 31 Mar 2026 |
| David E. I. Pyott |
3/4/5
Director
|
0.02%
|
$9,710,065
29,482 shares
|
-$1,145,853 | 01 Jun 2026 |
| Michael W. Bonney |
3/4/5
Director
|
0.02%
|
$8,824,800
20,804 shares
|
-$5,062,500 | 18 Aug 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
245
Shares
2,726,794
Rows available
245
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
786
Q2 2026 holders
245
Holder diff
-541
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|